The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou
about
Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological roleClinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable anginaAntioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a reviewPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionCrystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase: STRUCTURAL IMPLICATION TO LIPOPROTEIN BINDING AND CATALYSISPlatelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trialsEffect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trialLipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literatureThe inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.Impact of 8-week linoleic acid intake in soy oil on Lp-PLA2 activity in healthy adults.Lp-PLA2 Inhibition-The Atherosclerosis Panacea?n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetesLipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.Lp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsInhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.Anti-inflammatory therapies for cardiovascular diseaseCirculating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese populationCirculating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapyThe metabolic serine hydrolases and their functions in mammalian physiology and disease.Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European AncestryThe pharmacokinetics and safety of darapladib in subjects with severe renal impairment.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Determination of phospholipase activity of PAF acetylhydrolaseSelective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2)Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.Peripheral artery disease, biomarkers, and darapladib.Phospholipase A2 structure/function, mechanism, and signaling.
P2860
Q26747100-14125502-6EA2-4EAE-BEF4-0C9AB0BE1C6CQ26859111-AF968E4F-A2B3-4D10-9F2C-9310EC146CECQ26991853-C8C2745B-3378-4A21-955D-07E2011B7931Q26997377-9AD918BE-62C2-4B49-B612-ACA12B83626BQ27652078-4F53F9C9-687D-4216-8D41-4FF3ABB3936DQ28539153-7D7AD7AE-D78D-4479-ADE4-C26883A7F57EQ28539991-825F6B02-BD42-490D-8097-3752EDEC54DCQ33536648-1856787D-7FAD-4EE7-A73F-ECA14B42D40BQ33566165-B5AE56FF-B2A5-48DC-B612-58586C883D58Q33602983-6764037E-826F-4792-8A13-0476BECAD671Q33651282-2825D344-08D3-4D84-AC7E-0BBDA6C1858CQ33664272-55C248A6-11B6-4031-8E19-0F35BB1AA6CAQ33766630-3189816E-3CBA-485B-8B7B-BFC7AD86AB5AQ33768940-00D1476D-EE51-4C40-8455-9EC2776BCFF1Q33803486-5B41DBC0-3A8B-4D34-A435-BE28FF045D05Q33829154-669201E1-1E87-41A9-8FD2-81E99996414BQ33905460-4FD5528F-1599-487E-9A41-1F33D86C88BDQ33936097-588E3E09-1C83-4098-9F1C-4D7F8DC025A5Q34016317-60FF3B9C-42B8-4C58-BB2F-7FD41E11C319Q34137872-AAC3380A-AA90-47D5-B44F-B37E72CFD34EQ34167997-E5EB3D36-CF7C-4CBA-8FB3-75543C6FC994Q34214336-A8D11E6A-247A-4766-A612-2588A450DE46Q34384281-98478FD0-F190-4EA5-BEF4-0B528910FBE5Q34554918-8F8A42F8-16C4-47CF-949D-5D7613E3FED9Q34890672-4D0C823C-B2E9-4F30-92E9-6FC48FC8AB07Q34960396-4D0CEA2C-45E3-4427-AE7B-02514ED08610Q35169770-E0BC3D2F-15E9-403A-B597-70700DB6F094Q35267751-78FF8CCB-47C2-4DCC-870C-DDD4C98EB876Q35333042-DBC93A06-5B22-4D79-A8E6-86EE3B35CD17Q35616605-7D97A00D-311E-472D-A8E2-5DDAB93F24F1Q35774358-0EADF9BE-B216-4AFC-8B8D-1E19EF04143FQ36041389-10D3B204-2919-4236-8633-0CC648A996BDQ36125450-1B73C312-F84F-44F7-9E6F-FF0944046B66Q36145180-E23CA40C-B956-4C8C-8400-46529890DA4DQ36240691-B0C5C0D0-B3F6-4B88-B3A7-02B254D3CBA6Q36547608-97E7800A-04D5-4923-975C-8C121F10A87CQ36632984-47FF9D10-3D28-4386-8B00-935B782643FAQ37076194-D7D7DA49-B390-485B-93B3-BC469C1D26B5Q37114477-52E67159-D021-430D-8672-F14F0A4B8CEEQ37326136-797B0AC8-C0E8-4172-8715-BE0BAE72E9FF
P2860
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The effect of darapladib on pl ...... a multicenter, randomized, dou
@ast
The effect of darapladib on pl ...... a multicenter, randomized, dou
@en
The effect of darapladib on pl ...... a multicenter, randomized, dou
@nl
type
label
The effect of darapladib on pl ...... a multicenter, randomized, dou
@ast
The effect of darapladib on pl ...... a multicenter, randomized, dou
@en
The effect of darapladib on pl ...... a multicenter, randomized, dou
@nl
prefLabel
The effect of darapladib on pl ...... a multicenter, randomized, dou
@ast
The effect of darapladib on pl ...... a multicenter, randomized, dou
@en
The effect of darapladib on pl ...... a multicenter, randomized, dou
@nl
P2093
P921
P1476
The effect of darapladib on pl ...... a multicenter, randomized, dou
@en
P2093
Andrew Zalewski
Christie M Ballantyne
Darapladib Investigators
Emile R Mohler
Joel L Johnson
Michael H Davidson
P304
P356
10.1016/J.JACC.2007.11.079
P407
P577
2008-04-01T00:00:00Z